ArticleBMC cancer2017

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.

José Angel García-Saenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.